What is the relationship between invasive mucinous adenocarcinoma and genetic mutations?
Best insight from top research papers
Invasive mucinous adenocarcinoma (IMA) of the lung is associated with specific genetic mutations. Research has shown that IMAs are characterized by frequent KRAS mutations and gene fusions, particularly involving NRG1. Comprehensive molecular analysis of IMAs revealed that nearly all cases exhibit major oncogenic drivers, with KRAS mutations being the most common, followed by NRG1 fusions and ERBB2 alterations. Notably, NRG1-rearranged IMAs display more aggressive characteristics compared to KRAS-mutant IMAs, leading to worse recurrence-free survival outcomes. Additionally, targetable gene fusions were identified in a significant portion of KRAS wild-type IMAs, highlighting the importance of comprehensive molecular testing that includes fusion analysis for effective targeted therapy.
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
17 Apr 2023 | Mutant KRAS and FOXA2 cooperation drives invasive mucinous adenocarcinoma of the lung, with specific gene expression changes observed in comparison to normal lung tissue. |
02 May 2023 | Mutant KRAS cooperates with FOXA2 to drive invasive mucinous adenocarcinoma of the lung, as shown by differential gene expression in IMA compared to normal lung tissue. |
02 May 2023 | FOXA2 cooperates with mutant KRAS to drive invasive mucinous adenocarcinoma of the lung, indicating a relationship between genetic mutations and this specific type of cancer progression. |
| Invasive mucinous adenocarcinoma (IMA) is associated with genetic mutations like KRAS, NRG1 fusions, and ERBB2 alterations, with distinct aggressive characteristics observed in NRG1-rearranged tumors. | |
| Invasive mucinous adenocarcinoma (IMA) is associated with genetic mutations like KRAS, NRG1 fusions, and ERBB2 alterations, with distinct aggressive characteristics observed in NRG1-rearranged tumors. |
Related Questions
Can genetic mutation help in the treatment of cancer?5 answersGenetic mutations can help in the treatment of cancer by guiding personalized therapies and predicting treatment response. The administration of cancer drugs can be tailored to specific genetic tests, such as alterations in oncogenes or overproduction of proteins. For example, mutations in genes like EGFR, BRAF, HER2, ALK, and KRAS can be targeted with mutation-specific compounds. Additionally, machine learning algorithms based on gene mutations can predict treatment response with high accuracy, allowing for the development of biomarker models for personalized therapies. The extensive molecular characterization of tumors through next-generation sequencing has facilitated the identification of actionable mutations and the integration of multiomics data for drug sensitivity prediction. Rapid genomic testing upon diagnosis can also enable the early integration of novel therapies based on the tumor's somatic mutation status. Overall, genetic mutations play a crucial role in guiding cancer treatment and improving patient outcomes.
What is the relationship of mutation in codons?5 answersMutation in codons can have various effects on gene expression and protein function. Studies have shown that synonymous codon mutations can influence transcription and translation, leading to changes in gene expression levels. The genetic code has evolved to minimize the effects of mutations, and the severity of non-synonymous mutations in proteins can be influenced by the amino acid repertoire, codon usage, and environmental factors. The degree of mutation of a codon position can impact the evolutionary patterns of DNA or amino acid sequences. Synonymous mutations, although not changing the primary protein sequence, can affect various biological processes such as transcription, translation, and mRNA stability. Mutations in codons can have implications for disease pathogenesis, with certain codons and amino acids being more prone to mutation and affecting the physical properties of proteins.
How do mutations increase cancer cell survival?3 answersMutations increase cancer cell survival by affecting critical genes involved in regulating cell proliferation, differentiation, and cell death. These mutations can be gain-of-function mutations in oncogenes or loss-of-function mutations in tumor suppressor genes. Additionally, epigenetic mechanisms can alter the expression of proto-oncogenes and tumor suppressor genes, leading to similar consequences as gene mutations. The accumulation of multiple gene defects is necessary for the development of clinically recognizable cancer. Clonal selection plays a role in determining the specific genetic and epigenetic defects present in cancer cells, promoting the outgrowth of cells with mutations that confer proliferative and survival advantages. Cancer cells acquire traits such as increased stem cell-like phenotype, enhanced response to growth signals, resistance to growth inhibitors, increased mutation rate, angiogenesis, immune evasion, limitless cell division, invasion, and adaptation to different microenvironments. These traits are influenced by various gene defects and expression changes, which may have pleiotropic effects on cancer cell phenotype.
What ere new gen mutation in tumorigenesis pathway?5 answersNew gene mutations in the tumorigenesis pathway have been identified through various studies. One study aggregated genomic and transcriptomic data from breast, ovarian, and prostate cancers to identify novel cancer-causing mutations. They successfully identified 116 probable novel cancer-causing genes, including MXRA5, OBSCN, RYR1, and TG. Another study focused on the influence of various BRAF mutations in cancer, including the V600E mutant, which is associated with melanoma, colorectal cancer, and multiple myeloma. Additionally, the co-occurrence of multiple mutations in one tumor has been shown to contribute to cancer development. For example, the co-mutation TP53:KRAS in pancreatic adenocarcinoma is significantly associated with disease-specific survival. Mapping somatic mutations in normal human tissues has also provided insights into the genetic events that occur prior to tumorigenesis. These studies highlight the ongoing efforts to identify new gene mutations in the tumorigenesis pathway and their implications for cancer development and treatment.
What are the genetic risks for Mucoepidermoid Carcinoma?5 answersMucoepidermoid Carcinoma (MEC) is not specifically mentioned in the provided abstracts. Therefore, there is no direct information about the genetic risks for MEC in the abstracts.
What is the relationship between chemical mutagenesis and carcinogenesis?5 answersChemical mutagenesis and carcinogenesis are closely related processes. Mutagens are substances that can cause changes in DNA, such as mutations, while carcinogens are substances that can cause cancer. The link between mutagenesis and carcinogenesis is supported by various studies. Early observations of tumors in chimney sweeps and experiments with coal tars provided evidence that environmental carcinogens can promote cancer. Additionally, research on individuals exposed to radiation and studies on fly genetics suggested that carcinogens induce mutations in DNA, altering cell behavior and leading to cancer. Furthermore, the discovery that many chemicals undergo metabolic changes before becoming biologically active strengthened the correlation between mutagenicity and carcinogenicity. The capacity of chemicals to be converted into electrophilic derivatives, which can react with DNA and other cellular components, has been linked to their mutagenic and carcinogenic effects. Overall, the evidence suggests that chemical mutagenesis plays a significant role in the development of cancer.